Trial Profile

A Phase III Trial of Pegcantratinib in Patients with Psoriasis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 06 Aug 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegcantratinib (Primary)
Indications Psoriasis
Focus Registrational; Therapeutic Use
Sponsors Sienna Biopharmaceuticals

Most Recent Events

05 Aug 2019 According to a Sienna Biopharmaceuticals media release, the company will continue to explore capital raising to enable the initiation of the planned Phase 3 pivotal clinical trials for SNA-120 (pegcantratinib; CT profile 232992 and 305470), in addition to exploring a wide range of financial and strategic alternatives.The company does not intend to initiate these planned phase 3 trials of SNA-120 until the company secures sufficient additional capital.
10 Jun 2019 According to a Sienna Biopharmaceuticals media release, first patient enrollment is anticipated in the second half of 2019.
20 Mar 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com